Printer Friendly

US ONCOLOGY CENTER OFFERS AUSTCANCER'S REVISYS SUPPLEMENTS.

Through its US subsidiary ACT (USA), Australian Cancer Technology ("AustCancer" ASX:ACU) has announced that its full range of revisys specialty nutritional supplements are available at the new Center for integrative Health, founded by Dr. D. Barry Boyd at Greenwich Hospital - Yale Health. This new facility anticipates serving more than 1,000 patients annually.

The integrated, multi-level revisys products are designed to meet the complex nutritional needs that accompany aging or chronic health issues, such as for patients undergoing cancer treatment. ACT (USA) opened its U.S. headquarters in Rochester, New York late last year.

ACT (USA) CEO, Dr Mary Maida welcomed the tie-up with the Center for Integrative Health. "This deal offers a significant opportunity to be a part of a team of medical professionals and top physicians dedicated to integrative medicine," she said.

A member of the Yale New Haven Health System, Greenwich Hospital is a community teaching hospital affiliated with the Yale University School of Medicine and representing all medical specialties. To meet the needs of the surrounding communities, the hospital has expanded services and developed new programs. The new Center for Integrative Health. will be a unique facility incorporating health and wellness initiatives as well as educational outlets for patients to learn more about improving and maintaining health.

ACT's Dr Maida said that the mission of revisys is to become the leading choice of medical professionals for scientifically credible, high quality nutritional supplements. "The U.S. offers an $18.7 billion nutritional supplement market that is expected to grow to five times its current size by 2010. In the U.S., more than 60% of doctors are referring patients for services that are complementary to, and seamlessly integrate with mainstream medical therapies," she said.

ACT announced in February that it had appointed Strong Value Group, a leading healthcare marketing group in the United States, to distribute the revisys range nationally in a non-exclusive agreement expected to generate sales in excess of US$1 million in its first full year of operation.

AustCancer is developing a portfolio of high quality oncology-related projects that are at various stages of commercialization. Cash generating businesses such as revisys will provide the funds to exploit the potential of the company's leading product, the Phase II Pentrix vaccine, and to introduce promising pre-clinical and Phase I projects into the development pipeline. The revisys business is expected to be cash positive in its first year of operation.

About Australian Cancer Technology

Australian Cancer Technology is a broadly based international oncology company developing a portfolio of high quality oncology-related projects that are at various stages of commercialization. Cash generating businesses will provide the funds to exploit the potential of its leading products and to introduce promising pre-clinical and Phase I projects into the development pipeline. Its leading edge Pentrix anti-cancer vaccine successfully completed Phase I and Phase Ib/IIa trials at St. Vincent's Hospital Sydney and will soon undergo a comprehensive Phase II trial with prostate cancer patients in Melbourne. AustCancer's US subsidiary, revisys, is launching a range of nutritional supplements designed by leading US scientists for people with special needs, including those undergoing cancer treatment. That business is expected to be cash positive in year one. The company is also broadening its cancer therapeutic development pipeline, which currently includes a new oncology drug (CHK1 Kinase Inhibitor) to optimise the efficacy of chemotherapy and radiotherapy. AustCancer plans to list on NASDAQ in the near future.

For information, call 585/419-9710 or visit http://www.austcancer.com.au or http://www.revisyshealth.com.
COPYRIGHT 2004 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Date:Jun 1, 2004
Words:588
Previous Article:ANIKA INITIATES INCERT-S ANTI-ADHESION THERAPY CLINICAL TRIAL.
Next Article:DRAGON GETS HUMAN G-CSF LICENSING RIGHTS EXCLUDING CHINA.


Related Articles
United Bus. Media acquires Cliggott Publ. & Oncology Gp. from SCP Comm.
Kai Tiaki nursing New Zealand themes for the year ahead.
AUSTCANCER TO ACQUIRE U.S. VACCINE DEVELOPER.
AUSTCANCER APPOINTS SINGAPORE DISTRIBUTOR FOR REVISYS.
AustCancer Names PondelWilkinson as Strategic Investor Relations and Corporate Communications Counsel.
AustCancer Appoints New Vice President, Sales and Marketing to Boost Nutritional Products Business.
AustCancer Commences Phase II Clinical Study of RP101 for Metastatic Pancreatic Cancer.
Australian Cancer Technology Announces Change in Board Of Directors.
Australian Cancer Technology Provides Update on Ongoing Clinical Study of Pentrys Vaccine for Prostate Cancer.
Approach to communicating with patients about the use of nutritional supplements in cancer care.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters